Recalled Medicines & supplements – Current GIS Alerts 2026
Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
RANIC
This risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product containing ranitidine, which may affect human health and life. Potential effects: possible carcinogenic effects, liver damage, poisoning.
RANIBERL MAX
Suspected presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: carcinogenic action, organ damage with long-term exposure.
RANIGAST PRO
This risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life. Potential effects: poisoning, carcinogenic effects.
RANIGAST MAX
The risk may be caused by the potential presence of N-nitrosodimethylamine (NDMA) contamination in the medicinal product, which may affect human health and life and potentially endanger patients’ life or health. Potential effects: carcinogenic effects, liver damage, other toxic effects.
BICAVERA Z 1,5% GLUKOZĄ I WAPNIEM 1,25 MMOL/L
Potential quality defect of the primary packaging, which may affect the safety and quality of the peritoneal dialysis solution. Potential effects: complications during dialysis, infections, lack of treatment efficacy.
IBUFEN DLA DZIECI FORTE O SMAKU TRUSKAWKOWYM
A quality defect consisting of an out-of-specification result for the ibuprofen content parameter in the medicinal product Ibufen for children Forte, strawberry flavour. Potential effects: lack of treatment efficacy or overdose leading to adverse reactions.
BENZACNE
A defective internal lacquer coating was found on the inner surface of the primary packaging (tube) used for packing the medicinal product, creating a substantiated potential risk to patients’ health or life. Potential effects: health complications, possible loss of medicine quality or safety.
ZOLAXA RAPID
A quality defect was found: an out-of-specification result for the active substance content per tablet, which may mean an incorrect dose of the medicine for the patient. Potential effects: lack of treatment efficacy or increased adverse effects.
FOSIDAL O SMAKU MALINOWYM
A risk of use disproportionate to the therapeutic effect of the product containing fenspiride was identified, which may pose a real and highly probable threat to patients’ health or life. Potential effects: treatment complications, serious adverse reactions, threat to health or life.
EURESPAL
A risk of using the medicinal product Eurespal disproportionate to its therapeutic effect was identified, which may cause a significant threat to patients’ health or life. Potential effects: treatment complications, lack of efficacy, possible serious adverse reactions.
Elofen
Determination of a risk of use disproportionate to the therapeutic effect of the medicinal product Elofen, with a significant probability of harm to individuals and a real, highly probable threat to patients’ health or life. Potential effects: serious adverse reactions, complications, threat to health or life, lack of a favorable benefit‑risk balance.
FENSPOGAL
A risk of use disproportionate to the therapeutic effect was identified for products containing fenspiride, considered by PRAC and CMDh significant enough to recommend withdrawal of marketing authorizations. Potential effects: serious adverse reactions, risk to health or life, unacceptable safety profile.
PULNEO O SMAKU COLI
It was found that the benefit–risk ratio of medicinal products containing fenspiride is not favourable, and therefore withdrawal of marketing authorisations for these products was recommended. Potential effects: lack of adequate treatment efficacy, possible serious adverse reactions.
EURESPAL
A risk of use disproportionate to the therapeutic effect of the medicinal product Eurespal was identified, which may pose a direct threat to patients’ health or life. Potential effects: serious adverse reactions, threat to patients’ health or life.
EURESPAL
It was found that the benefit-risk balance of products containing fenspiride is unfavorable, meaning a risk of use disproportionate to the therapeutic effect and a potential threat to patients’ health or life. Potential effects: serious adverse reactions, life-threatening events, lack of safe therapy.
FOSIDAL O SMAKU POMARAŃCZOWYM
It was found that the risk of using products containing fenspiride is disproportionate to their therapeutic effect, with a potential threat to patients’ health or life. Potential effects: serious adverse reactions, complications and life‑threatening events.
PULNEO
It was determined that the benefit‑risk balance of medicinal products containing fenspiride, including Pulneo, is not favorable, which may pose a real threat to patients’ health or life. Potential effects: serious adverse reactions, threat to health or life.
EUREFIN
A risk of use of the medicinal product Eurefin disproportionate to its therapeutic effect was identified, meaning that the benefit–risk balance of medicines containing fenspiride is not favourable. Potential effects: serious adverse reactions, unacceptable safety profile, possible threat to patients’ health or life.
EURESPAL
A risk of use disproportionate to the therapeutic effect was identified for medicinal products containing fenspiride, meaning an unfavorable benefit–risk balance and potential health threat to patients. Potential effects: lack of treatment efficacy, complications from adverse reactions, risk to health or life.
PULNEO
A use-related risk disproportionate to the therapeutic effect was identified for medicinal products containing fenspiride, with the benefit–risk balance considered unfavorable, which may pose a real threat to patients’ health or life. Potential effects: lack of treatment efficacy, complications, and risk to patient health or life.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.